Publications in collaboration with researchers from Emory University School of Medicine (18)

2024

  1. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

2023

  1. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

    Blood cancer journal, Vol. 13, Núm. 1, pp. 116

2022

  1. Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies

    European Journal of Cancer, Vol. 174, pp. S31-S32

  2. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice

    The Lancet Haematology, Vol. 9, Núm. 2, pp. e162-e165

  3. Smoldering multiple myeloma current treatment algorithms

    Blood cancer journal, Vol. 12, Núm. 9, pp. 129

2021

  1. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  2. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2019

  1. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312

  2. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469

2018

  1. Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data

    The Lancet Neurology, Vol. 17, Núm. 1, pp. 47-53

2017

  1. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905

  2. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

    British Journal of Haematology, Vol. 178, Núm. 4, pp. 571-582

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346

  3. Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group

    Blood, Vol. 127, Núm. 24, pp. 2955-2962

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2014

  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548

2012

  1. Management of treatment-emergent peripheral neuropathy in multiple myeloma

    Leukemia, Vol. 26, Núm. 4, pp. 595-608